he 18th Annual Meeting of the International Conference on Genomics (ICG-18), titled ‘Collaboration for Omics: From the Electronic Century to the Biological Century’, was held in Singapore from April 22nd to 23rd.

Clinical research published in Nature Medicine and co-led by BGI-Research has demonstrated the safety and feasibility of a neoadjuvant immunotherapy medication for patients with locally advanced esophageal squamous cell carcinoma (ESCC), as well as introduced a crucial treatment response indicator, identified three tumor microenvironment phenotypes relevant to immunotherapy, and examined the reasons behind treatment efficacy or non-efficacy in specific patients.